Article Text
Abstract
Although cerebrospinal fluid (CSF) biomarker testing is incorporated into some current guidelines for the diagnosis of dementia (such as England's National Institute for Health and Care Excellence (NICE)), it is not widely accessible for most patients for whom biomarkers could potentially change management. Here we share our experience of running a clinical cognitive CSF service and discuss recent developments in laboratory testing including the use of the CSF amyloid-β 42/40 ratio and automated assay platforms. We highlight the importance of collaborative working between clinicians and laboratory staff, of preanalytical sample handling, and discuss the various factors influencing interpretation of the results in appropriate clinical contexts. We advocate for broadening access to CSF biomarkers by sharing clinical expertise, protocols and interpretation with colleagues working in psychiatry and elderly care, especially when access to CSF may be part of a pathway to disease-modifying treatments for Alzheimer’s disease and other forms of dementia.
- CSF
- alzheimer disease
- amyloid
- dementia
- health policy & practice
Statistics from Altmetric.com
Linked Articles
- Editors’ commentary
Read the full text or download the PDF:
Other content recommended for you
- Neurofilament light chain as a biomarker in neurological disorders
- Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers
- Neuropathology and emerging biomarkers in corticobasal syndrome
- Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia
- Biomarkers in dementia: clinical utility and new directions
- A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes
- Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid
- Amyloid PET imaging in clinical practice
- Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias
- Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum